Financial Analysis
Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data
Filing evidence summary
Mixed evidenceCoverage 5/5 core metricsLatest reported free cash flow was -$80M.
Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.
Evidence signals
- Free cash flow was negative
Latest reported free cash flow was -$80M.
Why this surfaced
Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2024-12-31.
- 8 filing risk checks flagged
Flagged areas: Earnings quality, Solvency & liquidity, Dilution.
Why this surfaced
The full financial analysis shows each value, threshold, and sector limitation.
- Revenue expanded
Latest reported annual revenue changed +11.1% from the prior reported annual observation.
Why this surfaced
Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.
- Operating margin improved
Operating margin changed +85.5 percentage points from the prior annual period.
Why this surfaced
Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.
Core trend metrics
Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.
Where to look next
Risk checks
- Earnings quality
- Solvency & liquidity
- Dilution
Financial movement
- Cash→ flat
- Long-term debt→ flat
- Inventory→ flat
- Receivables→ flat
- Current assets→ flat
Source & freshness
- Source
- SEC EDGAR XBRL
- Fetched
- 2026-09-06
- Latest period end
- 2025-12-31
- Filings
- EDGAR ↗
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Journey$61.9Mshare n/a+10.2% yoy
- Avenue Therapeutics Inc$1.4Mshare n/ano prior
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Checkpoint-$38M54.2%-32.3% yoy
- Fortress Biotech Inc-$18.5M26.3%+42.3% yoy
- Journey-$8.17M11.6%-40.3% yoy
- Avenue Therapeutics Inc-$3.08M4.4%-72.7% yoy
- Mustang Therapeutics Inc-$2.43M3.5%-85.0% yoy
Members sum to the consolidated -$70.2M for this period.
- Qbrexza$25M40.8%-0.4% yoy
- Emrosi$14.7M24.1%no prior
- Accutane$12.9M21.0%-33.6% yoy
- Foam Franchise Products$5.86M9.6%-11.9% yoy
- Other Legacy Product Revenue$2.74M4.5%-30.9% yoy
- Royalty$00.0%no prior
Members sum to the consolidated $61.2M for this period.
- Journey$16M99.5%no prior
- Fortress Biotech Inc$77K0.5%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
Peer percentiles
latest fiscal year ending 2025-12-31 · among 4,104 US-listed filers · 791 in Materials| Metric | Value | vs all filers | vs sector |
|---|---|---|---|
Revenue latest fiscal-year revenue as filed | $61M | 23rdof 3,301 bottom third | 39thof 522 middle third |
Revenue growth latest fiscal-year revenue vs the prior fiscal year | 11.1% | 64thof 3,135 middle third | 58thof 473 middle third |
Operating margin operating income ÷ revenue | -114.7% | 16thof 2,819 bottom third | 40thof 483 middle third |
Net margin net income ÷ revenue | 11.1% | 73rdof 3,263 top third | 82ndof 518 top third |
Return on equity net income ÷ stockholders' equity (positive equity only) | 13.7% | 77thof 3,577 top third | 87thof 701 top third |
Interest coverage operating income ÷ interest expense (interest expense > 0) | -7.0× | 25thof 819 bottom third | 49thof 155 middle third |
Stock comp ÷ revenue stock-based compensation ÷ revenue · lower is ranked higher | 46.9% | 10thof 2,895 bottom third | 26thof 476 bottom third |
Days sales outstanding receivables ÷ revenue × 365 · lower is ranked higher | 178 days | 4thof 2,398 bottom third | 7thof 387 bottom third |
Cash conversion operating cash flow ÷ net income (net income > 0) | -9.7× | 0thof 2,135 bottom third | 0thof 186 bottom third |
Cash-flow accrual ratio (net income − operating cash flow) ÷ average total assets · lower is ranked higher | 44.0% | 1stof 3,291 bottom third | 2ndof 588 bottom third |
Balance-sheet accrual ratio change in net operating assets ÷ average net operating assets · lower is ranked higher | 211.0% | 3rdof 2,805 bottom third | 6thof 517 bottom third |
Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.
Earnings quality
latest fiscal year ending 2025-12-31 · accruals and cash conversion as filedPer fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.
Point-in-time ledger
first-reported vs latest filing · periods since 2020-01-01 · 5 changed periods| Line item | Period | First reported | Latest filing | Change | Filings |
|---|---|---|---|---|---|
| Receivables AccountsReceivableNetCurrent | balance at 2020-12-31 | $19.3M 10-K 2021-03-31 | $23.9M 10-K 2022-03-28 | +23.7% | first · latest · 6 filings carry it |
| Long-term debt LongTermDebt | balance at 2025-12-31 | $52.4M 10-K 2026-03-31 | $54.5M 10-Q 2026-08-13 | +4.0% | first · latest · 3 filings carry it |
| Equity issued ProceedsFromIssuanceOfCommonStock | fiscal year 2020-12-31 | $47.5M 10-K 2021-03-31 | $45.9M 10-K 2022-03-28 | -3.5% | first · latest · 3 filings carry it |
| Total liabilities Liabilities | balance at 2020-12-31 | $132M 10-K 2021-03-31 | $136M 10-K 2022-03-28 | +3.5% | first · latest · 6 filings carry it |
| Total assets Assets | balance at 2020-12-31 | $329M 10-K 2021-03-31 | $333M 10-K 2022-03-28 | +1.4% | first · latest · 6 filings carry it |
7 share-count periods re-presented for a stock split (1-for-15) are listed apart from restatements and not counted above.
First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.
Notes by disclosure type
Not available for FBIO yet: no footnote text blocks on file for this filer in the ingested DERA files.
Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.